Search results
Results from the WOW.Com Content Network
Glycosuria leads to excessive water loss into the urine with resultant dehydration, a process called osmotic diuresis. Alimentary glycosuria is a temporary condition, when a high amount of carbohydrate is taken, it is rapidly absorbed in some cases where a part of the stomach is surgically removed, the excessive glucose appears in urine ...
Familial renal glycosuria (FRG) is caused by mutations of SLC5A2, which codes for the sodium-glucose cotransporter 2. [3] Additionally, SGLT2 inhibitor medications produce glycosuria as their primary mechanism of action, by inhibiting sodium/glucose cotransporter 2 in the kidneys and thereby interfering with renal glucose reabsorption.
Glucosuria causes a loss of hypotonic water and Na +, leading to a hypertonic state with signs of volume depletion, such as dry mucosa, hypotension, tachycardia, and decreased turgor of the skin. Use of some drugs, especially stimulants, may also increase blood glucose and thus increase urination. [citation needed].
GLP-1 medications are drugs that mimic the effects of the GLP-1 hormone, helping regulate blood sugar and reduce appetite. They are primarily used for managing type 2 diabetes but are also ...
A 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke or end-stage renal disease when comparing metformin monotherapy to dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes. [25]
This is an accepted version of this page This is the latest accepted revision, reviewed on 15 January 2025. Group of endocrine diseases characterized by high blood sugar levels This article is about the common insulin disorder. For the urine hyper-production disorder, see Diabetes insipidus. For other uses, see Diabetes (disambiguation). Medical condition Diabetes Universal blue circle symbol ...
Dapagliflozin is used along with diet, exercise, and usually with other glucose-lowering medications, to improve glycaemic control in adults with type 2 diabetes. . Dapagliflozin, in addition to other SGLT2-inhibitors, was shown to reduce the rate of decline in kidney function and kidney failure in non-diabetic and type 2 diabetic adults when added to the existing treatment
SGLT2 inhibitors (also called gliflozins or flozins) are a class of medications that inhibit sodium-glucose transport proteins in the nephron (the functional units of the kidney), unlike SGLT1 inhibitors that perform a similar function in the intestinal mucosa.